openPR Logo
Press release

Therapeutic Nuclear Medicines Market Opportunity Assessment 2018 - 2028 | Novartis AG, Bayer AG and GE Healthcare, Curium Pharmaceuticals, Jubilant DraxImage, Spectrum Pharmaceuticals

01-30-2019 12:51 PM CET | Health & Medicine

Press release from: Future Market Insights

Therapeutic Nuclear Medicines Market Opportunity Assessment

Increasing acceptance of therapeutic nuclear medicines (or radiopharmaceuticals) among industry experts will remain a prominent factor encouraging their adoption. Though associated with a negligible risk factor, radiopharmaceuticals are likely to witness growing recommendation owing to no proven significant adverse effects.

In the backdrop of the growing criticality of a more reliable, safer, and lesser harmful line of treatment for cancers, therapeutic nuclear medicines are being increasingly perceived as the potential treatment for cancer patients. Moreover, consistently surging instances of bone metastases further supports adoption growth, in the therapeutic nuclear medicines market.

Request to View a Sample Copy of This Report @ https://www.futuremarketinsights.com/reports/sample/rep-gb-2930

Just-under 10% Annual Growth Projected for Radiopharmaceuticals Adoption

A recent market research intelligence by Future Market Insights focuses on the deep-dive evaluation of global therapeutic nuclear medicines landscape, emphasizing the analysis of the most influential factors responsible for surging acceptance of radiopharmaceuticals in treating a range of cancers and a few other chronic conditions.

The study projects robust progress for the global radiopharmaceuticals market in coming years, reportedly driven by remarkable adoption in the treatment of prostate cancer. In 2019, the global demand for therapeutic nuclear medicines is expected to grow at a 9.7% annual rate, and maximum adoption is estimated by cancer research institutes at a global level.

North America, jointly with Western Europe, represents more than 65% share of the total market value.

Outpacing developed regional markets, the radiopharmaceuticals market in China and emerging economies across Asia Pacific, Latin America, and Middle East & Africa are slated for higher year on year revenue growth of over 12% in 2019 and ahead.

China is reportedly the most lucrative market for penetration of therapeutic nuclear medicines, which is attributed to an expanding cancer patient pool in the country and a consistently surging rate of radiopharmaceuticals recommendation.

Top Three Companies Account for More than 87% Market Value Share

A highly consolidated marketplace, global therapeutic nuclear medicines landscape is dominated by Bayer AG that currently accounts for just-under 80% revenue share in market. The top three players include GE Healthcare and Novartis AG other than Bayer, which collectively cover over 87% of the total valuation of radiopharmaceuticals market. While exceptional sales and success rate of Xofigo have been prominently retaining Bayer’s top position in the global market, strategic acquisitions are identified to be the key strategy behind Novartis’ success at a global level.

Thorough assessment of the competitive landscape of global therapeutic medicines market reveals a few prominent developmental strategies adopted by a majority of key companies operating in radiopharmaceuticals landscape –

Investments in R&D of targeted cancer therapeutics

Stronger supply chain and more streamlined distribution network

Improved flagship product sales

Strategic collaborations with pharma/biopharmaceutical companies

Contractual relationships with domestic/regional stakeholders

Strategic deals with internationally recognized cancer research institutes

Over 20% Growth Forecast for Erbium-169

Radium-223 has been the highest recommended type of radionucleotide in radiopharmaceuticals market. While it currently accounts for a whopping 78% share in the global market revenue, it is more likely that Erbium-169 that has been witnessing higher traction in recent past would witness relatively higher revenue growth in coming years. The report forecasts over 20% year on year revenue growth for Erbium-169 in 2019.

Get Report Customization Now @ https://www.futuremarketinsights.com/customization-available/rep-gb-2930

Exceptional Growth Projections for Thyroid & Brain Cancer

While over half the global market value is accounted by the adoption of therapeutic nuclear medicines for treatment of prostate cancer, bone metastases also accounts for sizable revenue generation in the market. Brain tumor and thyroid cancer are likely to emerge highly lucrative targets for manufacturers of therapeutic nuclear medicines, according to the report.

About Us

Future Market Insights is the premier provider of market intelligence and consulting services, serving clients in over 150 countries. FMI is headquartered in London, the global financial capital, and has delivery centers in the U.S. and India.

FMI’s research and consulting services help businesses around the globe navigate the challenges in a rapidly evolving marketplace with confidence and clarity. Our customized and syndicated market research reports deliver actionable insights that drive sustainable growth. We continuously track emerging trends and events in a broad range of end industries to ensure our clients prepare for the evolving needs of their consumers.

Contact Us

U.S. Office

616 Corporate Way, Suite 2-9018,

Valley Cottage, NY 10989,

United States

T: +1-347-918-3531

F: +1-845-579-5705

Email: sales@futuremarketinsights.com

Web: https://www.futuremarketinsights.com/

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Therapeutic Nuclear Medicines Market Opportunity Assessment 2018 - 2028 | Novartis AG, Bayer AG and GE Healthcare, Curium Pharmaceuticals, Jubilant DraxImage, Spectrum Pharmaceuticals here

News-ID: 1546146 • Views:

More Releases from Future Market Insights

Global Anesthesia Equipment Market to Reach USD 18.2 Billion by 2035
Global Anesthesia Equipment Market to Reach USD 18.2 Billion by 2035
The Anesthesia Equipment Market is witnessing robust growth, with its value estimated at USD 9.3 billion in 2025 and projected to nearly double to USD 18.2 billion by 2035. This growth trajectory represents a compound annual growth rate of 7.0%, driven by increasing surgical volumes, rising prevalence of chronic respiratory and cardiovascular disorders, and ongoing expansion of healthcare infrastructure. The market is undergoing transformative change, as both established manufacturers and
Intravascular Ultrasound Systems Market to Reach USD 1455.7 Million by 2035
Intravascular Ultrasound Systems Market to Reach USD 1455.7 Million by 2035
The intravascular ultrasound (IVUS) systems market is on track to record consistent growth over the next decade. Valued at USD 893.7 million in 2025, the market is expected to expand to USD 1455.7 million by 2035, reflecting a compound annual growth rate of 5.0%. With cardiovascular disease remaining one of the leading causes of mortality globally, the demand for advanced intravascular imaging technologies is escalating. IVUS systems, which provide real-time
Electric Power Sports Market to Reach USD 18.5 Billion by 2035
Electric Power Sports Market to Reach USD 18.5 Billion by 2035
The global Electric Power Sports Market is on a fast track to transformation, as consumers, manufacturers, and policymakers align on one powerful goal: sustainable, high-performance recreational experiences. Valued at USD 10.3 billion in 2025, the market is projected to expand to USD 18.5 billion by 2035, reflecting a steady compound annual growth rate (CAGR) of 6.0%. This momentum is set to generate an absolute dollar opportunity of USD 8.2 billion over
Hair Straightener Market Forecast to Reach USD 12.4 Billion by 2035 as Innovation and Consumer Demand Drive Growth
Hair Straightener Market Forecast to Reach USD 12.4 Billion by 2035 as Innovatio …
The global hair straightener market is entering a transformative growth phase, as industry leaders and emerging brands alike innovate to meet rising consumer demand for advanced hair styling solutions. Valued at USD 7.1 billion in 2025, the market is projected to reach USD 12.4 billion by 2035, registering a compound annual growth rate (CAGR) of 5.7% over the forecast period. Between 2025 and 2030, the market is set to rise steadily

All 5 Releases


More Releases for Bayer

Regorafenib Market Analysis By Top Key Players - Bayer Pharmaceuticals, Beacon P …
The "Regorafenib Market" is expected to reach USD xx.x billion by 2031, indicating a compound annual growth rate (CAGR) of xx.x percent from 2024 to 2031. The market was valued at USD xx.x billion In 2023. Growing Demand and Growth Potential in the Global Regorafenib Market, 2024-2031 Verified Market Research's most recent report, "Regorafenib Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2023-2030," provides an in-depth examination of the
Radiopharmaceuticals Market 2022 Sales Revenue - Bracco Imaging, Bayer, Mallinck …
Global Radiopharmaceuticals Market from 2022 to 2028 launched by MarketsandResearch.biz comprises a comprehensive market analysis that encompasses key aspects of the industry and defines current market dynamics in detail. It assesses growth patterns, magnitudes, and specific business developments under the current market scenario. The best statistical surveying and investigation performed with the advanced tools and techniques in this report. The study report shows a balanced presentation of statistical and theoretical
Point of Care Molecular Diagnostics Market Industry Analysis with Abaxis, Inc., …
The Point of Care Molecular Diagnostics Market is set to exceed USD 2.5 billion by 2024; according to a new research study published by Global Market Insights, Inc. Increasing awareness regarding pre-disease diagnosis along with growing incidence of infectious diseases will drive point of care molecular diagnostics market growth. Growing R&D focused on reducing time required for molecular tests will further propel industry growth. However, long product development time and
Companies Profiled in Point of Care Molecular Diagnostics Market are Abaxis, Inc …
Global Point of Care (PoC) molecular diagnostics market is poised to witness robust growth over the forecast period. Increasing infectious diseases incidence coupled with growing public awareness levels pertaining to pre-disease detection to control its occurrence will drive PoC molecular diagnostics market growth. Quick and precise detection of causative agents is of utmost importance in infectious disease emergency cases as the inaccuracy in disease detection leads to incorrect treatment which
Companies Profiled in Point of Care Molecular Diagnostics Market are Abaxis, Inc …
Global Point of Care (PoC) molecular diagnostics market is poised to witness robust growth over the forecast period. Increasing infectious diseases incidence coupled with growing public awareness levels pertaining to pre-disease detection to control its occurrence will drive PoC molecular diagnostics market growth. Quick and precise detection of causative agents is of utmost importance in infectious disease emergency cases as the inaccuracy in disease detection leads to incorrect treatment which
Drug Delivery Market 2018 | Johnson, Bayer
Report Summary The Global Drug Delivery Market Size is primarily driven by the increasing demand for technological advanced products that are used for drug delivery, and increased number of chronic diseases in the increasing number of geriatric population. Drug delivery is referred as drug administration in the human body through injections or various other devices. Drug delivery devices are used to inject the therapeutic substances in the body with the help of